Pharvaris/$PHVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pharvaris
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Ticker
$PHVS
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Zug, Switzerland
Employees
119
ISIN
NL00150005Y4
Website
Pharvaris Metrics
BasicAdvanced
$1.3B
-
-$3.27
-2.86
-
Price and volume
Market cap
$1.3B
Beta
-2.86
52-week high
$26.33
52-week low
$11.51
Average daily volume
62K
Financial strength
Current ratio
11.1
Quick ratio
10.782
Long term debt to equity
0.242
Total debt to equity
0.329
Profitability
EBITDA (TTM)
-185.312
Effective tax rate (TTM)
-1.22%
Management effectiveness
Return on assets (TTM)
-31.88%
Return on equity (TTM)
-52.20%
Valuation
Price to book
5.74
Price to tangible book (TTM)
5.74
Price to free cash flow (TTM)
-8.198
Free cash flow yield (TTM)
-12.20%
Free cash flow per share (TTM)
-289.46%
Growth
Earnings per share change (TTM)
14.86%
3-year earnings per share growth (CAGR)
24.82%
What the Analysts think about Pharvaris
Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.
Bulls say / Bears say
Pharvaris's lead drug candidate, deucrictibant, has received orphan designation from the European Commission, highlighting its potential as a novel oral treatment for hereditary angioedema (HAE). (Pharvaris News Releases)
Analysts at JMP Securities have maintained a 'Market Outperform' rating with a $55 price target, citing the company's strong financial position and upcoming Phase 3 data for deucrictibant. (Investing.com)
Pharvaris has initiated enrollment in its Phase 3 RAPIDe-3 trial for the on-demand treatment of HAE attacks, demonstrating effective execution of its clinical strategy. (Investing.com)
Pharvaris reported a net loss of $30 million in Q1 2024, with operating expenses exceeding expectations due to elevated R&D costs. (Investing.com)
The company's stock has experienced volatility, trading between $11.83 and $25.01 over the past year, reflecting typical fluctuations in biotech firms during developmental phases. (DirectorsTalk Interviews)
Pharvaris's financials show a negative free cash flow of -$79.65 million, underscoring the capital-intensive nature of its ongoing clinical trials. (DirectorsTalk Interviews)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Pharvaris Financial Performance
Revenues and expenses
Pharvaris Earnings Performance
Company profitability
Pharvaris News
AllArticlesVideos
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
GlobeNewsWire·1 week ago
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
GlobeNewsWire·3 weeks ago
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharvaris stock?
Pharvaris (PHVS) has a market cap of $1.3B as of July 18, 2025.
What is the P/E ratio for Pharvaris stock?
The price to earnings (P/E) ratio for Pharvaris (PHVS) stock is 0 as of July 18, 2025.
Does Pharvaris stock pay dividends?
No, Pharvaris (PHVS) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Pharvaris dividend payment date?
Pharvaris (PHVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharvaris?
Pharvaris (PHVS) has a beta rating of -2.86. This means that it has an inverse relation to market volatility.